Literature DB >> 26716907

Low bone mineral density in achondroplasia and hypochondroplasia.

Masaki Matsushita1, Hiroshi Kitoh1, Kenichi Mishima1, Izumi Kadono1, Hiroshi Sugiura1, Sachi Hasegawa1, Yoshihiro Nishida1, Naoki Ishiguro1.   

Abstract

BACKGROUND: Achondroplasia (ACH) and hypochondroplasia (HCH) are the most common form of short-limb skeletal dysplasias caused by activated fibroblast growth factor receptor 3 (FGFR3) signaling. Although decreased bone mass was reported in gain-of-function mutation in Fgfr3 mice, both disorders have never been described as osteoporotic. In the present study, we evaluated bone mineral density (BMD) in ACH and HCH patients.
METHODS: We measured spinal BMD (L1-L4) in 18 ACH and four HCH patients with an average age of 19.8 ± 7.5 years (range, 10-33 years). BMD Z-score in each individual was calculated for normalizing age and gender. Correlation between body mass index (BMI) and BMD was analyzed. Moreover, BMD and Z-score were compared between ACH patients and HCH patients.
RESULTS: The average BMD of ACH/HCH patients was 0.805 ± 0.141 g/cm(2) (range, 0.554-1.056 g/cm(2) ), resulting in an average Z-score of -1.1 ± 0.8 (range, -2.4 to 0.6) of the standard value. A slightly positive correlation was observed between BMI and BMD (r = 0.45; P = 0.13). There was no significant difference in BMD and Z-score between ACH and HCH patients.
CONCLUSION: Spinal BMD was reduced in ACH/HCH patients, and was mildly correlated with individual BMI. We should carefully monitor BMD and examine osteoporosis-related symptoms in adolescent and adult ACH/HCH patients.
© 2016 Japan Pediatric Society. © 2015 Japan Pediatric Society.

Entities:  

Keywords:  achondroplasia; bone mineral density; fibroblast growth factor receptor 3; hypochondroplasia; osteoporosis

Mesh:

Substances:

Year:  2016        PMID: 26716907     DOI: 10.1111/ped.12890

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  9 in total

Review 1.  Low Energy Availability, Menstrual Dysfunction, and Low Bone Mineral Density in Individuals with a Disability: Implications for the Para Athlete Population.

Authors:  Cheri A Blauwet; Emily M Brook; Adam S Tenforde; Elizabeth Broad; Caroline H Hu; Eliza Abdu-Glass; Elizabeth G Matzkin
Journal:  Sports Med       Date:  2017-09       Impact factor: 11.136

Review 2.  The Emerging Role of Glucose Metabolism in Cartilage Development.

Authors:  Judith M Hollander; Li Zeng
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

3.  Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.

Authors:  Mohammed Salman Shazeeb; Megan K Cox; Anurag Gupta; Wen Tang; Kuldeep Singh; Cynthia T Pryce; Robert Fogle; Ying Mu; William D Weber; Dinesh S Bangari; Xiaoyou Ying; Yves Sabbagh
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

4.  Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.

Authors:  Masaki Matsushita; Ryusaku Esaki; Kenichi Mishima; Naoki Ishiguro; Kinji Ohno; Hiroshi Kitoh
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

5.  Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.

Authors:  Yi-Ching Lee; I-Wen Song; Ya-Ju Pai; Sheng-De Chen; Yuan-Tsong Chen
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

6.  Whole-body and segmental analysis of body composition in adult males with achondroplasia using dual X-ray absorptiometry.

Authors:  David Sims; Gladys Onambélé-Pearson; Adrian Burden; Carl Payton; Christopher Morse
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

Review 7.  Current knowledge of medical complications in adults with achondroplasia: A scoping review.

Authors:  Svein O Fredwall; Grethe Maanum; Heidi Johansen; Hildegun Snekkevik; Ravi Savarirayan; Ingeborg B Lidal
Journal:  Clin Genet       Date:  2019-04-22       Impact factor: 4.438

8.  Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.

Authors:  Leia C Shuhaibar; Nabil Kaci; Jeremy R Egbert; Thibault Horville; Léa Loisay; Giulia Vigone; Tracy F Uliasz; Emilie Dambroise; Mark R Swingle; Richard E Honkanen; Martin Biosse Duplan; Laurinda A Jaffe; Laurence Legeai-Mallet
Journal:  JCI Insight       Date:  2021-05-10

9.  Bone mineral density in mucopolysaccharidosis IVB.

Authors:  Francyne Kubaski; Heidi H Kecskemethy; H Theodore Harcke; Shunji Tomatsu
Journal:  Mol Genet Metab Rep       Date:  2016-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.